Targeting epigenetic alterations in cancer stem cells

Area of Science:

• Epigenetics
• Cancer Biology
• Stem Cell Research
• Regenerative Medicine

Background:

• Pediatric tumors and some adult cancers show rare mutations in oncogenes or tumor suppressor genes.
• This suggests epigenetic reprogramming plays a critical role in tumorigenesis.
• Cancer stem cells (CSCs), derived from normal stem cells (NSCs) via epigenetic deregulation, possess self-renewal, metastatic, and chemo-resistant properties.

Purpose of the Study:

• To provide an overview of the role of aberrant epigenetic modifications in CSC initiation, formation, and maintenance.
• To review epigenetic inhibitors in clinical trials targeting CSCs.
• To discuss epigenetic drugs and stem cells in regenerative medicine for cancer and other diseases.

Main Methods:

• Literature review and synthesis of existing research on epigenetic alterations in cancer stem cells.
• Analysis of current clinical trials involving epigenetic inhibitors for CSC targeting.
• Exploration of the application of epigenetic drugs and stem cells in regenerative medicine.

Main Results:

• Aberrant epigenetic modifications are crucial for the initiation, formation, and maintenance of cancer stem cells.
• Several epigenetic inhibitors are in clinical trials, showing potential for specifically targeting CSCs.
• Epigenetic drugs and stem cell-based therapies hold promise for regenerative medicine applications in cancer and diseases.

Conclusions:

• Understanding the epigenetic landscape of CSCs is key to developing targeted therapies against aggressive cancer subpopulations.
• Epigenetic reprogramming is a central mechanism in the transformation of normal stem cells into cancer stem cells.
• This knowledge provides a framework for novel therapeutic strategies in oncology and regenerative medicine.